Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if orally-administered recombinant human
lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients
who have failed at least one prior systemic therapy for RCC.